Skip to content

Study · Case report or series · 2019

8 results

LTX-315 sequentially promotes lymphocyte-independent and lymphocyte-dependent antitumor effects.

Liao HW, Garris C, Pfirschke C, Rickelt S, Arlauckas S, Siwicki M, Kohler RH, Weissleder R, Sundvold-Gjerstad V, Sveinbjørnsson B, Rekdal Ø, Pittet MJ

Cell stress14 Oct 2019Cited by 27 (Europe PMC)

PMID31799501 (opens in a new tab)PMCIDPMC6859426 (opens in a new tab)DOI10.15698/cst2019.11.204 (opens in a new tab)PepBankPUB-31799501
Download PDFPubMedAsk about this study
Jump to 8 results

Summary

LTX-315 is an oncolytic peptide that has antitumor efficacy in mice grafted with various tumor cell lines and is currently being tested in phase II clinical trials. Here we aimed to further evaluate LTX-315 in conditional genetic mouse models of cancer that typically resist current treatment options and to better understand the drug's mode of action in vivo. We report LTX-315 mediates profound antitumor effects against Braf- and Pten-driven melanoma and delays the progression of Kras- and P53-driven soft tissue sarcoma in mice. Additionally, we show in melanoma that LTX-315 triggers two sequential phases of antitumor response. The first phase of response, which begins within minutes of drug delivery into tumors, is defined by disrupted tumor vasculature and decreased tumor burden and occurs independently of lymphocytes. The second phase of response, which continues over weeks, is defined by long-term alteration of the tumor microenvironment; the changes induced by LTX-315 are most notably characterized by CD8+ T cell infiltration. We further show that these CD8+ T cells are involved in suppressing melanoma outgrowth in mice and report similar CD8+ T cell infiltration following LTX-315 treatment in melanoma and sarcoma patients. Taken together, these findings reveal LTX-315's multiple antitumor effects, including disrupting the tumor vasculature and promoting the conversion of poorly immunogenic tumors into ones that display antitumor T cell immunity.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study8

8 results from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesMechanism

    In melanoma and sarcoma patients, LTX‑315 treatment was followed by CD8+ T-cell infiltration.

    In plain wordsIn melanoma and sarcoma patients, LTX‑315 treatment was followed by CD8+ immune cell infiltration.

    Peptide
    LTX-315
    Outcome
    IncreaseHuman tumor CD8+ T-cell infiltration
    Study

    n: not reported in source

    Outcome group
    Immune response · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We further show that these CD8+ T cells are involved in suppressing melanoma outgrowth in mice and report similar CD8+ T cell infiltration following LTX-315 treatment in melanoma and sarcoma patients.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with Braf- and Pten-driven melanoma, LTX‑315 produced profound antitumor effects.

    In plain wordsIn mice with melanoma, LTX‑315 produced profound effects against tumors.

    Peptide
    LTX-315
    Outcome
    DecreaseMelanoma antitumor effect
    Study

    mousen: not reported in source

    Braf- and Pten-driven melanoma
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · intratumoralAs given in this study (mouse).

    Source sentences

    Summary
    We report LTX-315 mediates profound antitumor effects against Braf- and Pten-driven melanoma and delays the progression of Kras- and P53-driven soft tissue sarcoma in mice.
    1 context sentence
    Summary · context
    Here we aimed to further evaluate LTX-315 in conditional genetic mouse models of cancer that typically resist current treatment options and to better understand the drug's mode of action in vivo.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice with Kras- and P53-driven soft tissue sarcoma, LTX‑315 delayed disease progression.

    In plain wordsIn mice with soft tissue sarcoma, LTX‑315 delayed disease progression.

    Peptide
    LTX-315
    Outcome
    DecreaseSarcoma progression
    Study

    mousen: not reported in source

    Kras- and P53-driven soft tissue sarcoma
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · intratumoralAs given in this study (mouse).

    Source sentences

    Summary
    We report LTX-315 mediates profound antitumor effects against Braf- and Pten-driven melanoma and delays the progression of Kras- and P53-driven soft tissue sarcoma in mice.
    1 context sentence
    Summary · context
    Here we aimed to further evaluate LTX-315 in conditional genetic mouse models of cancer that typically resist current treatment options and to better understand the drug's mode of action in vivo.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In mouse melanoma, the early LTX‑315 response disrupted tumor vasculature independently of lymphocytes.

    In plain wordsIn mice with melanoma, the early LTX‑315 response disrupted tumor blood vessels independently of lymphocytes.

    Peptide
    LTX-315
    Outcome
    Not applicableTumor vasculature disruption
    Study

    mousen: not reported in source

    melanoma
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated · intratumoralAs given in this study (mouse).

    Source sentences

    Summary
    The first phase of response, which begins within minutes of drug delivery into tumors, is defined by disrupted tumor vasculature and decreased tumor burden and occurs independently of lymphocytes.
    1 context sentence
    Summary · context
    Here we aimed to further evaluate LTX-315 in conditional genetic mouse models of cancer that typically resist current treatment options and to better understand the drug's mode of action in vivo.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In mouse melanoma, the early LTX‑315 response decreased tumor burden independently of lymphocytes.

    In plain wordsIn mice with melanoma, the early LTX‑315 response decreased tumor burden independently of lymphocytes.

    Peptide
    LTX-315
    Outcome
    DecreaseEarly tumor burden
    Study

    mousen: not reported in source

    melanoma
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · intratumoralAs given in this study (mouse).

    Source sentences

    Summary
    The first phase of response, which begins within minutes of drug delivery into tumors, is defined by disrupted tumor vasculature and decreased tumor burden and occurs independently of lymphocytes.
    1 context sentence
    Summary · context
    Here we aimed to further evaluate LTX-315 in conditional genetic mouse models of cancer that typically resist current treatment options and to better understand the drug's mode of action in vivo.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In mouse melanoma, LTX‑315 caused long-term tumor microenvironment changes during a response that continued over weeks.

    In plain wordsIn mice with melanoma, LTX‑315 changed the tumor environment during a response that continued over weeks.

    Peptide
    LTX-315
    Outcome
    Not applicableLong-term tumor microenvironment alteration
    Study

    mousen: not reported in source

    melanoma
    Outcome group
    Immune response · Cancer
    Studied dose
    Dose not stated · intratumoralAs given in this study (mouse).

    Source sentences

    Summary
    The second phase of response, which continues over weeks, is defined by long-term alteration of the tumor microenvironment; the changes induced by LTX-315 are most notably characterized by CD8+ T cell infiltration.
    1 context sentence
    Summary · context
    Here we aimed to further evaluate LTX-315 in conditional genetic mouse models of cancer that typically resist current treatment options and to better understand the drug's mode of action in vivo.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In mouse melanoma, LTX‑315 promoted CD8+ T-cell infiltration during the later response.

    In plain wordsIn mice with melanoma, LTX‑315 promoted CD8+ immune cell infiltration during the later response.

    Peptide
    LTX-315
    Outcome
    IncreaseCD8+ T-cell infiltration
    Study

    mousen: not reported in source

    melanoma
    Outcome group
    Immune response · Cancer
    Studied dose
    Dose not stated · intratumoralAs given in this study (mouse).

    Source sentences

    Summary
    The second phase of response, which continues over weeks, is defined by long-term alteration of the tumor microenvironment; the changes induced by LTX-315 are most notably characterized by CD8+ T cell infiltration.
    1 context sentence
    Summary · context
    Here we aimed to further evaluate LTX-315 in conditional genetic mouse models of cancer that typically resist current treatment options and to better understand the drug's mode of action in vivo.
  8. 08AnimalAnimal study (in vivo)Mechanism

    In mice, CD8+ T cells associated with LTX‑315 treatment contributed to suppression of melanoma outgrowth.

    In plain wordsIn mice, CD8+ immune cells associated with LTX‑315 treatment helped suppress melanoma growth.

    Peptide
    LTX-315
    Outcome
    DecreaseCD8+ T-cell-dependent outgrowth suppression
    Study

    mousen: not reported in source

    melanoma
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · intratumoralAs given in this study (mouse).

    Source sentences

    Summary
    We further show that these CD8+ T cells are involved in suppressing melanoma outgrowth in mice and report similar CD8+ T cell infiltration following LTX-315 treatment in melanoma and sarcoma patients.
    1 context sentence
    Summary · context
    Here we aimed to further evaluate LTX-315 in conditional genetic mouse models of cancer that typically resist current treatment options and to better understand the drug's mode of action in vivo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.